ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB350

Association of 24-Hour Urinary Oxalate Excretion with Cardiovascular Disease in Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Bannister, Lillian Elizabeth, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States
  • Dixon, Angelina Magreni, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States
  • You, Zhiying, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States
  • Kendrick, Jessica B., University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States
Background

Urinary oxalate has been associated with mortality in kidney transplant recipients (KTR). Whether urinary oxalate is a risk factor for cardiovascular disease (CVD) in kidney transplant recipients is unclear.

Methods

We studied 54 stable KTR with a functioning allograft ≥1 year. Urinary oxalate excretion was determined from a 24-hour urine collection. Finger reactive hyperemic index (RHI) and aortic pulse wave velocity (PWV), both of which are predictors of CVD outcomes, were determined using EndoPAT (peripheral artery tonometry) and Sphygmocor, respectively. Linear regression was used to evaluate the association between urinary oxalate excretion and RHI and PWV.

Results

The mean (SD) age and eGFR were 50.0 (14.8) years and 66.5 (16.8) ml/min/1.73m2. 75.9% were men and 25.9% had diabetes. Mean (SD) 24-hour urinary oxalate was 34.7 (14.5) mg/day. 24-hour urinary oxalate excretion was not significantly associated with RHI or aPWV in unadjusted or fully adjusted analyses, but there was a trend towards significance in the fully adjusted analyses (Table 1).

Conclusion

24-hour urinary oxalate excretion was not associated with intermediate markers of CVD. Whether impaired oxalate metabolism represents a novel therapeutic target for CVD in KTR needs to be determined in larger studies.

VariableUnadjusted β-estimate (95% CI)Fully Adjusted* β-estimate (95% CI)
RHI0.003 (-0.002 to 0.01), p=0.240.01 (-0.0004 to 0.01), p=0.06
PWV-0.01 (-0.05 to 0.02), p=0.38-0.03 (-0.05, to 0.002), p=0.07

*Adjusted for age, sex, race/ethnicity, history of diabetes and hypertension

Funding

  • NIDDK Support

Digital Object Identifier (DOI)